BioSpace News Archive

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® T-cell activating technology, today announced its financial results for the year ended December 31, 2020 and provided a business update.

Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced that it has dosed the first participants in the Company’s Phase 1 trial of its novel, oxygen enhancing therapeutic, trans sodium crocetinate (“TSC”), utilizing a transcutaneous oxygen monitoring

Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the appointment of Alexis A. Thompson, M.D., M.P.H., a world-renowned hematologist and sickle cell disease (SCD) expert, to the company’s board of directors.

Established in vivo genome editing research collaboration and exclusive license agreement with Eli Lilly Reported interim data from Phase 1/2a study of PBCAR0191; updated interim data expected by mid-year 2021 Interim data releases expected from PBCAR269A and PBCAR20A in 2021 Received FDA acceptance of IND application for PBCAR19B, a next-generation, stealth cell, anti-CD19 allogeneic CAR T candidate for non-Hodgkin lymphoma;

U.S. Renal Care, a leading provider of dialysis services, who cares for more than 26,000 Americans living with kidney disease, announced its request that the Biden administration designate its 350+ care centers as COVID-19 vaccination points-of-dispensing for dialysis patients and their frontline care staff.

Prelude Corporation (PreludeDx ™ ), a leader in molecular diagnostics and precision medicine for early stage breast cancer, presented data at the Society of Surgical Oncology (SSO) 2021 International Conference on Surgical Cancer

Financials : Full year 2020 net revenues of approximately $64 million , with gross profit of approximately $27.5 million Solid cash balance of approximately $100 million as of March 4, 2021 Planned commercial operational breakeven by the end of 2021

Company Founded by MPM Capital, with Financing Co-Led by MPM Capital, EcoR1 Capital and Vida Ventures Proprietary Technology Platform Harnesses the Power of Alpha Particles to Target Solid Tumors

LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and other major Asian markets, today announced the appointment of Yi Larson as Chief Financial Officer, effective May 1, 2021. Ms. Larson will be based in the Company’s Shanghai headquarters.

Conference Call and Webcast Today at 8:30 a.m. ET COVID-19 vaccine candidate, COVAXIN™, demonstrates efficacy of 81% in Phase 3 interim results Emergency Use Authorization pathway with U.S. regulatory authorities in development for COVAXIN™ European Commission grants orphan medicinal product designation for OCU400 for retinitis pigmentosa and leber congenital amaurosis and Ocugen is on track to submit an Investigational New Drug application for OCU400 in 2021